Lovastatin
| Evidence Level: L3 | Predicted Indications: 6 |
Table of Contents
- Lovastatin
- Lovastatin: From Statin Therapy for Hypercholesterolemia to Homozygous Familial Hypercholesterolemia
Lovastatin: From Statin Therapy for Hypercholesterolemia to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Lovastatin is an HMG-CoA reductase inhibitor (statin) marketed in the US as an oral tablet for lowering cholesterol. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolemia (HoFH). This direction has 3 registered clinical trials and 20 publications, but none of the trials tests lovastatin and the lovastatin-specific papers are small studies and case reports, so the evidence is weak and partly negative.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the supplied label data (lovastatin is a marketed statin used for hypercholesterolemia; check the label) |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed are all ANDAs, i.e. generics) |
| Recommended Decision | Hold (research question) |
Why is This Prediction Reasonable?
Lovastatin inhibits HMG-CoA reductase, which lowers cholesterol synthesis in the liver. This upregulates hepatic LDL receptors and increases LDL clearance. Detailed mechanism data were not available from DrugBank for this report. The description above comes from the candidate’s rationale analysis.
HoFH is a severe form of familial hypercholesterolemia with extremely high LDL-C. Because statins act mainly by upregulating LDL receptors, the mechanism fits only partly. Patients with some residual receptor function may respond. In receptor-negative patients there is little receptor activity to upregulate, so little effect is expected.
The literature matches this pattern:
- A 1988 study of three children with receptor-negative HoFH found no LDL-C reduction on lovastatin.
- Small reports from 1986 and 1990 show variable responses, mostly when lovastatin was combined with liver transplantation or LDL plasmapheresis.
- Overall, response appears to depend on residual receptor function.
Clinical Trial Evidence
All three trials are Phase 3 and completed, but none tests lovastatin. They cover ezetimibe and alirocumab in HoFH and give only statin-class background.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10 mg added to atorvastatin or simvastatin in HoFH; efficacy and safety. No lovastatin arm |
| NCT03885921 | Phase 3 | Completed | 44 | Up to 24-month open-label safety extension of ezetimibe added to atorvastatin or simvastatin in HoFH. No lovastatin arm |
| NCT03510715 | Phase 3 | Completed | 18 | Open-label alirocumab in children and adolescents (8–17 years) with HoFH; LDL-C at Week 12. Lovastatin is not an intervention |
Literature Evidence
Only the lovastatin-specific papers bear directly on this question. They are small studies and case reports.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3397806 | 1988 | Clinical study (3 children) | J Pediatr | Lovastatin at 2 mg/kg/day did not lower LDL-C or change LDL turnover in receptor-negative HoFH |
| 12034651 | 2002 | RCT (not lovastatin) | Circulation | Ezetimibe added to atorvastatin or simvastatin in 50 HoFH patients; background-statin context only |
| 1785747 | 1991 | Clinical study (2 patients) | An Esp Pediatr | Lovastatin combined with probucol and cholestyramine, analyzed against LDL receptor status |
| 2209665 | 1990 | Clinical study (1 child) | Eur J Pediatr | 7-year-old girl treated with LDL plasmapheresis (HELP), with and without lovastatin |
| 12091863 | 2002 | Case report | J Pediatr | Statins plus HELP apheresis for 15 years gave an 85% LDL-C reduction (statin not specified) |
| 3534334 | 1986 | Case report | JAMA | Child with HoFH after liver transplantation; lovastatin was added to lower cholesterol further |
| 12063772 | 2001 | Review | Nutr Metab Cardiovasc Dis | Why and when to use statins in children with familial hypercholesterolemia |
| 2042836 | 1991 | Review | Ann N Y Acad Sci | Drug and surgical options in dyslipidemic children, including lovastatin |
| 8637439 | 1996 | Case report | Metabolism | Sitosterolemia; effects of cholestyramine and lovastatin on plasma sterols (related but different disease) |
| 29284604 | 2018 | Cohort | Arterioscler Thromb Vasc Biol | HoFH patients with identical mutations vary in LDLR expression, which affects evolocumab response |
US Market Information
Lovastatin is sold as an oral tablet. The approved indication text is empty in the supplied data. Several manufacturers share the same application number.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA078296 | Lovastatin (Lupin Pharmaceuticals, Inc.) | Tablet | Not stated in supplied data |
| ANDA078296 | Lovastatin (Preferred Pharmaceuticals, Inc.) | Tablet | Not stated in supplied data |
| ANDA075991 | Lovastatin (NuCare Pharmaceuticals, Inc.) | Tablet | Not stated in supplied data |
| ANDA078296 | Lovastatin (BluePoint Laboratories) | Tablet | Not stated in supplied data |
| ANDA078296 | Lovastatin (Proficient Rx LP) | Tablet | Not stated in supplied data |
Safety Considerations
- Drug Interactions: The interaction query returned no records. The literature retrieved for this report does note severe myopathy and rhabdomyolysis with lovastatin plus gemfibrozil (12 FDA case reports, PMID 2355431) and with lovastatin plus nicotinic acid (PMID 3421570).
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is very high, but no registered trial tests lovastatin in HoFH. The lovastatin-specific evidence is limited to small studies and case reports, including a negative result in receptor-negative patients. The mechanism depends on residual LDL receptor function, so any benefit would likely be limited to a subset of patients. Guideline HoFH regimens rely on other agents, such as ezetimibe and PCSK9 inhibitors.
To proceed, the following is needed:
- Check the current US label for on-label status and the approved indication text, which is blank in the supplied data.
- Get lovastatin-specific data in HoFH stratified by LDL receptor status (receptor-negative vs. receptor-defective).
- Obtain the package insert warnings and contraindications, which are not in the data supplied.
- Obtain mechanism data from DrugBank for a fuller mechanistic analysis.
- Consider prioritizing the familial hypercholesterolemia (heterozygous) prediction from the same pack. It has stronger lovastatin-specific support: RCTs in adolescent boys and girls and a Phase 2/3 placebo-controlled study (NCT00116870, whose study population still needs confirming).
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.